A new study published by JAMA Network Open finds that 49 top-selling brand-name drugs saw a median price increase of 76% from January 2012 through December 2017.
All but one of those 49 drugs saw regular annual or biannual price increases, with no evidence that time on market or the availability of generic competitors affected prices. Of the 36 drugs in the study that were on the market since 2012, 28 saw prices rise by more than 50%, and 16 more than doubled in price.
“With so few exceptions to this norm, costs will likely continue to rise unless bold actions are taken,” the authors from the Scripps Research Institute conclude.
